Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders-Reference-Cited by-同舟云学术

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders

Published:2016-01-05 Issue:1 Volume:11 Page:e0145375
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Walz Johanna M.,Boehringer Daniel,Deissler Heidrun L.,Faerber Lothar,Goepfert Jens C.,Heiduschka Peter,Kleeberger Susannah M.,Klettner Alexa,Krohne Tim U.,Schneiderhan-Marra Nicole,Ziemssen Focke,Stahl Andreas

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. The biology of VEGF and its receptors;N Ferrara;Nature medicine,2003

2. Angiogenesis in cancer, vascular, rheumatoid and other disease;J Folkman;Nature medicine,1995

3. Improved survival with bevacizumab in advanced cervical cancer;KS Tewari;The New England journal of medicine,2014

4. Angiogenesis in brain tumours;RK Jain;Nature reviews Neuroscience,2007

5. Angiogenesis and vascular remodeling in chronic airway diseases;VK Alagappan;Cell biochemistry and biophysics,2013

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF-A165a and angiopoietin-2 differently affect the barrier formed by retinal endothelial cells;Experimental Eye Research;2024-10

2. A systematic review and meta-analysis of preanalytical factors and methodological differences influencing the measurement of circulating vascular endothelial growth factor;PLOS ONE;2022-07-06

3. Impairment of the Retinal Endothelial Cell Barrier Induced by Long-Term Treatment with VEGF-A165 No Longer Depends on the Growth Factor’s Presence;Biomolecules;2022-05-23

4. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells;Experimental Eye Research;2022-03

5. Changes in Systemic Levels of Vascular Endothelial Growth Factor After Intravitreal Injection of Aflibercept or Brolucizumab for Neovascular Age-Related Macular Degeneration;Retina;2021-11-01